We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 21

Federal circuit applies ariad analysis to dna and protein claims in interference

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • September 21 2010

The written description requirement of 35 U.S.C. 112 can play a critical role in interferences as well as patent prosecution and litigation

Preventive care court decision

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • November 19 2012

A federal judge in the District of Columbia circuit issued a stay from the contraceptive coverage mandate

11th Circuit upholds Broward County

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • August 21 2012

Yesterday, the US Court of Appeals for the 11th Circuit upheld summary judgment in favor of the employer in Seff v. Broward County

Supreme Court decision to drop on Thursday

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • June 25 2012

This morning the Supreme Court issued its ruling on the constitutionally of Arizona’s new immigration law

Method of treatment claims alive and well

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • December 20 2010

On December 17, 2010, the Federal Circuit issued its decision in Prometheus v. Mayo sustaining the patentability of Prometheus’s medical treatment claims

Separate written description? Oral arguments in en banc rehearing of Ariad v. Lilly

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • December 8 2009

The U.S. Court of Appeals for the Federal Circuit heard oral arguments on December 7 in its en banc rehearing of Ariad Pharmaceuticals Inc. v. Eli Lilly & Co., Fed. Cir., No. 2008-1248

Medical syringe company finds competitors’ mark a sticking point; pricks its ire

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • August 21 2012

In DuoProSS Meditech Corp. v. Inviro Medical Devices, Ltd., No 2012-1050, 2012 WL 3292920 (Fed. Cir. Aug. 14, 2012), the U.S. Court of Appeals for the Federal Circuit ruled that the Trademark Trial and Appeal Board erred in failing to cancel two trademark registrations for medical syringes designed to be broken so they could not be reused

Patentability of medical method patents after Bilski

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • July 12 2010

The Supreme Court's rejection in Bilski of the machine-or-transformation test as the sole test for determining patentability of a process has generated discussion in the medical device field as to the patentability of method patents, particularly in regard to diagnostic methods and methods of treatment

FTC v. Phoebe Putney Health System, Inc., et al.

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • February 20 2013

On February 19, 2013, the United States Supreme Court in Federal Trade Commission v. Phoebe Putney Health System, Inc., et al., unanimously rejected

Federal Circuit's en banc decision delineates and defines a written description requirement

  • Kilpatrick Townsend & Stockton LLP
  • -
  • USA
  • -
  • March 24 2010

On March 22, the Federal Circuit issued its 9-2 en banc decision in Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., affirming 112, 1 contains a written description requirement that is separate and distinct from the enablement requirement